On October 6, 2025, Maze Therapeutics announced the appointment of Hervé Hoppenot as Chairman of its Board of Directors, succeeding Charles Homcy, M.D., who will continue to serve on the board. Hoppenot brings more than three decades of experience in therapeutic development and commercial leadership, most recently serving as Chief Executive Officer of Incyte Corporation from 2014 to 2025 and as Chairman of Incyte from 2015 to 2025. He also held senior positions at Novartis, including President of Novartis Oncology and Chief Commercial Officer, and has a track record of transforming single‑product companies into diversified biopharmaceutical leaders.
Maze’s CEO Jason Coloma praised Hoppenot’s experience, noting that his leadership will help accelerate the company’s progress toward key milestones in 2026, including the initiation of Phase 2 trials for MZE782 and the release of Phase 2 data for MZE829. Coloma highlighted that Hoppenot’s background in oncology and large‑scale commercialization will be instrumental in guiding Maze’s precision‑medicine strategy and expanding its pipeline of small‑molecule therapies for kidney and metabolic diseases.
The appointment is significant for investors because it brings a seasoned executive with a proven track record of scaling biopharmaceutical companies to the helm of Maze’s board. Hoppenot’s experience in navigating regulatory pathways, securing large‑scale funding, and driving product development aligns with Maze’s current focus on advancing its lead programs, MZE829 and MZE782, into later‑stage trials. The continuity of former chairman Charles Homcy on the board also ensures stability during the transition, reinforcing confidence in the company’s governance and strategic direction.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.